BioTime is starting well behind Advanced Cell Technology, but has the advantage from a resource/partnership perspective and clinical grade stem cell line. BioTime recently announced it has filed an IND with the FDA for its stem cell therapy designed to treat patients with Dry-AMD.
http://ift.tt/1s5RuP8
http://ift.tt/1s5RuP8
No comments:
Post a Comment